A new report from GBI Reserch available from Reportlinker.com, "Hospital-Acquired Bacterial Infections Market to 2017," predicts that this market will decline at a negative CAGR of 3.4 percent in the forecast period of 2010 to 2017.
The global hospital-acquired bacterial infections (HABI)Â market mainly comprises of four indications which are urinary tract infections (UTIs), pneumonia, bloodstream infections (BSIs) and surgical site infections (SSIs). The total market of HABI is dependent on the major infections which are mainly caused by multidrug-resistant bacteria. Increasing human resistance to antibacterials leads to a need for advanced therapies to treat bacterial infections.
Patent expiry of major antibacterials like Zyvox, Invanz, Tobi and Levaquin is set to erode the HABI market, according to the report. This decline in the market will not be corrected by new product launches of pipeline molecules. Pharmaceutical companies show less interest in antibacterial R&D due to low return on investment. The lifespan of antibacterials is frequently limited due to the development of drug resistance. Big Pharma prefers acquiring small and niche pharmaceutical companies to widen its antibacterial pipeline portfolio.
According to the report, decline in the HABI market will be due to two main factors. Firstly, there is resistance developed against antibacterials which makes existing antibacterials obsolete in some conditions. Secondly, there is an increase in hospital surveillance which leads to a decline in HABIs. Based on Centers for Disease Control and Prevention (CDC) data, 20 percent to 30 percent of hospital acquired infections can be prevented by infection control programs. There is formation of government bodies which are making it mandatory for hospitals to cut down on the spread of infections in the healthcare environment.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.